KRAS-blocking drugs in pancreatic cancer: what the first studies show

The question

KRAS works like a stuck accelerator inside the tumor cell: it keeps the signal to grow switched on all the time. For decades, no one managed to block it with a drug. In recent years, the first medicines able to do so have appeared, but each was tested in small studies with only a few dozen patients. We wanted to know what these studies show when looked at together.

What we did

We carried out a systematic review with meta-analysis: we searched for all published early-phase studies and combined their results. Five studies were included, with 301 patients with advanced pancreatic cancer and five different drugs: sotorasib, adagrasib, daraxonrasib, zoldonrasib and GFH375.

What we found

In about one in four patients, the tumor shrank significantly, and this result was very similar across studies. For a cancer in which chemotherapy after the first line of treatment rarely shrinks the tumor, that is a strong signal. The time until the disease started growing again varied between drugs, from about 4 to 8.5 months.

The most common side effects were diarrhea, in almost half of patients, and nausea, in slightly fewer than half, and they were usually manageable.

What this means for you

These results confirmed that blocking KRAS works in pancreatic cancer and helped justify the larger studies that followed. One of them, RASolute 302, led to the approval of daraxonrasib in the United States in 2026: in previously treated patients, median survival went from 6.7 months with chemotherapy to 13.2 months with the new drug.

The limitations

These were early studies, without a comparison group and with few patients each. In some of them, the response did not last very long. So the conclusion is that this approach is promising, not that the problem is solved: larger studies are needed, along with markers that show who benefits most.

For information only. It does not replace an individual medical assessment.